Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Roswell Park Comprehensive Cancer Center, Buffalo

Winship Cancer Institute of Emory University, Atlanta

University of Miami-Sylvester Comprehensive Cancer Center, Miami

Norton Cancer Institute, St Matthews Campus, Louisville

Cleveland Clinic Taussig Cancer Institute, Cleveland

University of Michigan, Ann Arbor

Rush University Cancer Center, Chicago

The University of Kansas Cancer Center, Fairway

The University of Texas MD Anderson Cancer Center,, Houston

University of Colorado Cancer Center, Aurora

USC/Norris Comprehensive Cancer Center, Los Angeles

University of California, Hellen Diller Family Comprehensive Cancer Center, San Francisco

Oregon Health & Science University, Portland

John Theurer Cancer Center, Hackensack University Medical Center, Hackensack

Vanderbilt Ingram Cancer Center, Nashville